VOLITIONRX LIMITED 2,250,000 SHARES OF COMMON STOCK UNDERWRITING AGREEMENTAgreement • September 30th, 2016 • Volitionrx LTD • In vitro & in vivo diagnostic substances • New York
VolitionRx Limited, a Delaware corporation (the “Company”) proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule VI hereto (each, an “Underwriter” and collectively, the “Underwriters”), for whom National Securities Corporation is acting as representative (the “Representative”), an aggregate of 2,250,000 authorized but unissued shares (the “Firm Shares”) of its Common Stock, par value $0.001 per share (the “Common Stock”) and, at the election of the Underwriters, upon the terms and conditions stated herein, up to an additional 337,500 shares of Common Stock (the “Additional Shares” and together with the Firm Shares, the “Securities”).
